FDA decision: Ivonescimab by Summit Therapeutics (this year)
As of Tue, 20 Oct 2026 11:11:58 UTC, Kalshi traders price Yes (48.0%). The market has $9K in volume and closes on Fri, 01 Jan 2027.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Yes | 48.0% | 48.0¢ | 52.0¢ |
Market details
- Venue: Kalshi
- Volume: $9K
- Liquidity: $9K
- Closes:
Resolution rules
If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time. It was developed by Akeso and is being commercialized outside China by Summit Therapeutics. By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time. This market and these products have not been endorsed by any aforementioned brands or its affiliates. Any references to the brand, or any associated marks are descriptive only and do not indicate an endorsement of this product or any affiliation between the brand or its affiliates and Kalshi.
Sources
Related markets
- S&P close price end of 2026?
- Nasdaq-100 price on Sep 30, 2026 at 4pm EDT?
- Nasdaq-100 close price end of 2026?
- When will Anthropic officially announce an IPO?
- Who will successfully take over Warner Brothers?
- When will Apple release the iPhone 18?
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.